Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
Rhea-AI Summary
Shattuck Labs (NASDAQ: STTK) will present a prerecorded fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026 at 2:00 PM ET. Presenters include Taylor Schreiber, M.D., Ph.D. (CEO), Andrew R. Neill (CFO), and Michael Choi, M.D. (VP Clinical Development).
A replay of the prerecorded presentation will be available on the company’s Events and Presentations webpage starting at 2:00 PM ET on February 12, 2026, and will be archived for up to 30 days following the presentation date.
Positive
- None.
Negative
- None.
News Market Reaction – STTK
In the Feb 6 session, STTK gained 5.60%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Inducement option grant | Neutral | -3.9% | Equity awards for new hire under Nasdaq inducement rule with 10-year term. |
| Nov 20 | Investor conferences | Neutral | -1.5% | Management participation in December 2025 investor conferences and fireside chats. |
| Nov 06 | Earnings and pipeline | Positive | +1.0% | Q3 2025 results, SL-325 IND clearance, first dosing, and funding into 2029. |
| Oct 02 | KOL panel participation | Neutral | -0.4% | Company participation in Wedbush KOL and company panel after UEGW 2025. |
| Aug 26 | Private placement & board | Positive | +2.6% | Up to $103M private placement and board refresh supporting immunology focus. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent informational and corporate governance/news items have typically produced modest price moves, with more material financing and earnings updates seeing small positive reactions.
Over the past six months, STTK has issued several corporate and financing updates. A private placement of up to $103 million and board changes on Aug 26, 2025 coincided with a 2.65% gain, while Q3 2025 earnings on Nov 6, 2025 with $86.1M in cash and funding into 2029 saw a 1.02% rise. In contrast, routine items such as conference participation and inducement option grants in late 2025 produced small negative moves. Today’s conference-participation news fits this pattern of largely informational disclosures.
Key Terms
tumor necrosis factor (tnf) superfamily receptors medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium, taking place February 12-13, 2026.
Conference Details
Conference: Piper Sandler Virtual Novel Targets in Immunology Symposium
Format: Fireside chat
Presenters: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, Andrew R. Neill, Chief Financial Officer, and Michael Choi, M.D., Vice President of Clinical Development
Presentation Date: February 12, 2026
Time: 2:00 PM ET
Webcast link: HERE
A replay of the prerecorded presentation from the Piper Sandler Virtual Novel Targets in Immunology Symposium fireside chat will be available on the Events and Presentations section of the Company’s website starting at 2:00 PM ET on Thursday, February 12, 2026. A replay of the webcast will be archived for up to 30 days following the presentation date.
About SL-325
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is a fully Fc-silenced humanized immunoglobin G monoclonal antibody with a favorable safety profile in non-human primates, currently being evaluated in a Phase 1 clinical trial.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a clinical-stage biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
